These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27810613)

  • 21. Atomoxetine-Related Trichotillomania in a Boy with Attention-Deficit/Hyperactivity Disorder.
    Akaltun İ; Kara T
    J Child Adolesc Psychopharmacol; 2017 Dec; 27(10):923. PubMed ID: 29099621
    [No Abstract]   [Full Text] [Related]  

  • 22. Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD.
    Snircova E; Marcincakova-Husarova V; Hrtanek I; Kulhan T; Ondrejka I; Nosalova G
    Pediatr Int; 2016 Jun; 58(6):476-81. PubMed ID: 26579704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suicidal ideation among children taking atomoxetine (Strattera).
    Wooltorton E
    CMAJ; 2005 Dec; 173(12):1447. PubMed ID: 16330634
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
    Ruggiero S; Rafaniello C; Bravaccio C; Grimaldi G; Granato R; Pascotto A; Sportiello L; Parretta E; Rinaldi B; Panei P; Rossi F; Capuano A
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):415-22. PubMed ID: 23234585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impulsivity in Alcohol-Dependent Patients with and without ADHD: The Role of Atomoxetine.
    Coppola M; Mondola R
    J Psychoactive Drugs; 2018; 50(4):361-366. PubMed ID: 29877779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.
    Schwartz S; Correll CU
    J Am Acad Child Adolesc Psychiatry; 2014 Feb; 53(2):174-87. PubMed ID: 24472252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of medication on intraocular pressure in children with attention deficit hyperactivity disorder: A prospective study.
    Guvenmez O; Cubuk M; Gunes S
    J Popul Ther Clin Pharmacol; 2020 May; 27(2):e45-e50. PubMed ID: 32379404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder.
    Shang CY; Yan CG; Lin HY; Tseng WY; Castellanos FX; Gau SS
    Psychol Med; 2016 Nov; 46(15):3173-3185. PubMed ID: 27574878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atomoxetine-Associated Possible Abnormal Uterine Bleeding in an Adolescent: A Case Report.
    Açikel SB
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):339-340. PubMed ID: 33814545
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
    Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD.
    Upadhyaya H; Tanaka Y; Lipsius S; Kryzhanovskaya LA; Lane JR; Escobar R; Trzepacz PT; Allen AJ
    Postgrad Med; 2015; 127(7):677-85. PubMed ID: 26329980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
    Holzer B; Lopes V; Lehman R
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.
    Savill NC; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill D
    CNS Drugs; 2015 Feb; 29(2):131-51. PubMed ID: 25698145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.
    Cunill R; Castells X; Tobias A; Capellà D
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):961-9. PubMed ID: 23813665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
    Brown JT; Bishop JR; Sangkuhl K; Nurmi EL; Mueller DJ; Dinh JC; Gaedigk A; Klein TE; Caudle KE; McCracken JT; de Leon J; Leeder JS
    Clin Pharmacol Ther; 2019 Jul; 106(1):94-102. PubMed ID: 30801677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute suicidality after commencing atomoxetine.
    Paxton GA; Cranswick NE
    J Paediatr Child Health; 2008 Oct; 44(10):596-8. PubMed ID: 19012633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
    Prasad S; Steer C
    Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
    Liu Q; Zhang H; Fang Q; Qin L
    J Clin Exp Neuropsychol; 2017 Nov; 39(9):854-865. PubMed ID: 28052720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.